Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

PloS one - 1 Jan 2013

Winckelmann Anni A, Munk-Petersen Lærke V, Rasmussen Thomas A, Melchjorsen Jesper, Hjelholt Thomas J, Montefiori David, Østergaard Lars, Søgaard Ole S, Tolstrup Martin

Abstract excerpt

Toll-like receptor (TLR) agonists can reactivate HIV from latently infected cells in vitro. We aimed to investigate the TLR-9 agonist, CPG 7909's in vivo effect on the proviral HIV reservoir and HIV-specific immunity. This was a post-hoc analysis of a double-blind randomized controlled vaccine trial. HIV-infected adults were randomized 1:1 to receive pneumococcal vaccines with or without 1 mg CPG 7909 as adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Compartmentation
Share to Disease Reservoirs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Antibodies

Share to Immunity

Share to Immunologic Memory

Share to Oligodeoxyribonucleotides

Share to Proviruses

Share to Toll-Like Receptor 9

Source

Open in PubMed Open full text

Identifiers

PMID: 23637967
DOI: 10.1371/journal.pone.0062074
PMCID: PMC3637371

Genes

TLR9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.PMID 23637967Read ↗

Antiinfective Applications of Toll-like Receptor 9 AgonistsSemantic proximity Read ↗

Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes.Semantic proximity Read ↗

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.Semantic proximity Read ↗

TLR Agonists Enhance HIV-Specific T-Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression PhenotypesSemantic proximity Read ↗

Dynamics of anal HPV infection after 9vHPV vaccination in men who have sex with men (MSM) with HIV: A prospective, controlled cohort study.Semantic proximity Read ↗

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Semantic proximity Read ↗

CpG Oligodeoxynucleotides Activate HIV Replication in Latently Infected Human T CellsSemantic proximity Read ↗

Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.Semantic proximity Read ↗

Magnitude of Type I Interferon Responses by Plasmacytoid Dendritic Cells After TLR7 Stimulation Is Associated With Human Immunodeficiency Virus Type 1 (HIV-1) Reservoir Sizes in Cisgender Women With HIV-1 on Antiretroviral TherapySemantic proximity Read ↗

Human Galectin-9 Is a Potent Mediator of HIV Transcription and ReactivationSemantic proximity Read ↗

The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapySemantic proximity Read ↗

Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.